I work in the area between pre-clinical and clinical drug development for the treatment of tuberculosis. My focus is the development and application of mathematical and computational tools to better translate experimental studies to dose selection for clinical trials. This work involves both conventional pharmacokinetic/pharmacodynamic modeling and simulation as well as physiological modeling and the use of engineering-based approaches to design optimized combination drug regimens.
Ph.D, Purdue University, 1992MS, Marquette University, 1987BS, Marquette University, 1984
Reisfeld B, Ivy JH, Lyons MA, Wright JM, Rogers JL, Mayeno AN.
DoseSim: a tool for pharmacokinetic/pharmacodynamic analysis and dose reconstruction. Bioinformatics. 2013 Feb 1;29(3): PMID: 23162056
Lyons MA. Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment. J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):613-23. PMID: 25173151Weijs L, Roach AC, Yang RS, McDougall R, Lyons M, Housand C, Tibax D, Manning T, Chapman J, Edge K, Covaci A, Blust R. Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations.
Chemosphere. 2014 Jan;94:91-6.
Lyons MA, Reisfeld B, Yang RS, Lenaerts AJ. A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob Agents Chemother.
2013 Apr;57(4):1763-71. PMID: 23357766
Reisfeld B, Metzler CP, Lyons MA, Mayeno AN, Brooks EJ, Degroote MA.
A physiologically based pharmacokinetic model for capreomycin.
Antimicrob Agents Chemother. 2012. Feb;56(2):926-3
Lyons MA, Lenaerts AJ. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model. 2015 May 31; J Pharmacokinet Pharmacodyn. PMID: 26026426